FDMT4D Molecular Therapeutics, Inc.
What is the market doing?
No clear lean: nothing decisive, though a crowded short (+20% of shares).
Choppy, but holding above its 200-day average. Price is +0% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 22, 2026; selling is often routine (taxes, diversification).
A crowded short, settled Sep 30, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How FDMT is trading
4D Molecular Therapeutics, Inc. is +2.5% over the past year while the S&P 500 is +16%: 14 points behind the market.
1-year return · S&P 500 +16%
- vs 200-day average
- +0.15%
vs 200-day average · close to trend
- RSI (14)
- 35
RSI (14) · neutral
- Below its 52-week high
- 36%
Below its 52-week high
Details›
- Last close2026-10-23
- $10.78
- 1 monthS&P 500 −0.94%
- −27%
- 1 yearS&P 500 +16%
- +2.5%
- 5 yearsS&P 500 +86%
- −61%
- vs 50-day average$13.99
- −23%
- 52-week high
- $16.74
- 52-week low
- $7.19
- Annualised volatility
- 87%
| Year | Return |
|---|---|
| 2026 (year to date) | +44% |
| 2025 | +35% |
| 2024 | −73% |
| 2023 | −8.8% |
| 2022 | +1.2% |
| 2021 | −47% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 6 | 3 of 6 | −4.5% |
| Feb | 6 | 2 of 6 | +4.9% |
| Mar | 6 | 3 of 6 | −2.6% |
| Apr | 6 | 2 of 6 | −8.8% |
| May | 6 | 4 of 6 | −7.7% |
| Jun | 6 | 2 of 6 | +0.88% |
| Jul | 6 | 4 of 6 | +3.6% |
| Aug | 6 | 3 of 6 | +9.3% |
| Sep | 6 | 3 of 6 | −2.8% |
| Oct | 6 | 2 of 6 | −6.2% |
| Nov | 5 | 3 of 5 | +39% |
| Dec | 5 | 1 of 5 | −3.6% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.